Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Start with insulin-producing islets
What ifWhat if the culture starts with isolated donor islets that already secrete insulin?
Isolate intact islets from donor pancreatic tissue and maintain them in suspension culture. Measure insulin released at low and high glucose concentrations to identify preparations that retain glucose-responsive secretion.
1.1Stimulate proliferation with a small molecule
What ifWhat if a small-molecule kinase inhibitor provides the proliferation stimulus in culture?
Claim language“a polypeptide according to SEQ ID NO 1 or 2”
Expose isolated human islets to a small-molecule inhibitor of dual-specificity tyrosine phosphorylation-regulated kinase 1A. Inhibiting the kinase increases nuclear retention of a transcription factor that promotes cell-cycle entry. Quantify DNA synthesis in insulin-positive cells and measure glucose-stimulated insulin secretion after washout.
1.2Measure beta-cell DNA synthesis
What ifWhat if insulin staining and a thymidine analog identify insulin-producing cells that enter S phase?
Claim language“a CD133 cell marker and a Ki-67 cell marker”
Expose a culture aliquot to a thymidine analog during a defined labeling window and detect its incorporation into newly synthesized DNA. Co-stain for intracellular insulin and report the fraction of insulin-positive cells that incorporate the analog.
1.2Set a secretion threshold
What ifWhat if a minimum glucose-stimulated insulin output determines whether a cell batch passes?
Claim language“at least 60% of the AIPC population”
Expose matched aliquots of the batch to low and high glucose and measure insulin in the culture supernatants with an immunoassay. Apply acceptance limits to insulin output per viable cell and to the ratio of high-glucose to low-glucose secretion.
1.3Deliver insulin through a wearable pump
What ifWhat if insulin reaches the patient from an external pump without implanting the cell preparation?
Claim language“implantation into a mammal”
A wearable glucose sensor feeds readings to a controller that adjusts an external pump. The pump delivers insulin from a replaceable reservoir through a subcutaneous infusion cannula.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Plate assay for chemical exposure
Pancreatic cells are cultured with the activating polypeptide, and the resulting islet cell population is distributed into multiwell plates for chemical screening. Replicate wells receive a test chemical or its vehicle. After exposure, the wells receive sequential low- and high-glucose challenges, and the insulin released during each challenge is measured and normalized to viable cell count.
Component substitution
Serum-free basal medium for islet culture
A chemically defined, serum-free basal formulation supplies the salts, glucose, amino acids, and vitamins in the activation medium. The activating polypeptide is added to this formulation before the isolated non-insulin-producing pancreatic cells are introduced. A harvest aliquot is stained for CD133 and Ki-67, and a separate aliquot is challenged with glucose to measure insulin secretion.
Parameter or scale variation
Parallel expansion in multilayer culture vessels
Four ten-layer culture vessels replace a single culture vessel during expansion. Each layer receives the same volume of polypeptide-containing medium per unit surface area and the same starting cell density per unit surface area. Each vessel is sampled separately for viability, CD133 and Ki-67 coexpression, and glucose-stimulated insulin secretion before its cells are pooled.
Combination with existing systems
Islet cells in a retrievable implant
The expanded cells are loaded through a fill port into the shallow chamber of a retrievable macroencapsulation device. Semipermeable membranes on both faces allow oxygen, glucose, and insulin to diffuse while retaining the cells. The fill port is sealed before the device is implanted in a subcutaneous pocket.
Flow-through measurement of insulin secretion
An aliquot of the expanded islet cell population is placed in a temperature-controlled perifusion chamber fitted with a cell-retaining mesh. A valve switches the inlet between low- and high-glucose buffer while a pump holds the flow rate constant. A fraction collector captures the outlet stream at fixed intervals, and an insulin immunoassay measures the timing and magnitude of secretion.
Automated or data-driven variant
Image-based control of culture harvest
An incubator-mounted phase-contrast microscope images fixed fields in the culture vessel every six hours. Image segmentation software estimates the fraction of surface occupied by cells and initiates harvest when the median field reaches a preset occupancy threshold. A separate harvest sample is analyzed by flow cytometry for CD133 and Ki-67 coexpression, and a viable aliquot is tested for glucose-stimulated insulin secretion.
Specific version of a part
Culture in a defined medium
Use a defined basal medium containing glucose, amino acids, vitamins and buffered salts. Supplement it with the polypeptide identified by sequence 1 or 2 and use a concentration series to select the dose that supports expansion of the target cell population.
Count cells by flow cytometry
Stain surface CD133 before fixation and stain nuclear Ki-67 after permeabilization. Use flow cytometry to determine whether at least 60% of single cells in the sample carry both markers.
Measure insulin content and release
Measure intracellular insulin in a lysed aliquot and measure secreted insulin in buffer collected after sequential low- and high-glucose incubations of a matched aliquot. Normalize both measurements to viable cell count and report stimulated secretion relative to basal secretion.
Implant cells in a pouch
Load the cell preparation into a semipermeable pouch and place it in a subcutaneous pocket in a mammal with type 1 diabetes. Glucose and oxygen diffuse into the pouch, and secreted insulin diffuses into the surrounding tissue.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1an activated islet proliferating cell (AIPC) population obtained by a process comprising: culturing an isolated non-insulin producing pancreatic cell population in vitro with a cell culture medium comprising a base medium and an effective amount of a polypeptide according to SEQ ID NO 1 or 2 to generate the AIPC population
Thus, provided herein is a method of enhancing a population of insulin secreting cells (e.g., pancreatic islet cells) for transplantation. The method includes culturing the cell population with an exogeneous GDNF receptor agonist (for example, GDNF).
A · US 2008/0187522 A1 · ¶ 35
A method of generating an activated islet proliferating cell (AIPC) population, comprising: culturing a population of pancreatic islets in vitro with a cell culture medium comprising a base medium and an effective amount of an active agent to obtain the AIPC population, wherein at least 60% of the AIPC population is comprised of a CD133 cell marker and a Ki-67 cell marker; wherein at least 60% of the AIPC population is capable of insulin production; and wherein the active age
B · US 2021/0205371 A1 · claim 1
1.2wherein at least 60% of the AIPC population is comprised of a CD133 cell marker and a Ki-67 cell marker and is capable of insulin production and secretion
Since the total number of insulin secreting cells is increased by promoting proliferation or by reducing cell death, there are more cells to release insulin. Thus the population of insulin secreting cells is enhanced to release more insulin as compared to a control.
A · US 2008/0187522 A1 · ¶ 35
A method of generating an activated islet proliferating cell (AIPC) population, comprising: culturing a population of pancreatic islets in vitro with a cell culture medium comprising a base medium and an effective amount of an active agent to obtain the AIPC population, wherein at least 60% of the AIPC population is comprised of a CD133 cell marker and a Ki-67 cell marker; wherein at least 60% of the AIPC population is capable of insulin production; and wherein the active age
B · US 2021/0205371 A1 · claim 1
1.3wherein the composition is used for implantation into a mammal for in vivo therapy, specifically for treating Type I diabetes.
Also provided herein is a method of treating diabetes (type 1 or type 2) in a subject by administering to the subject a transplant composition comprising glial cells and insulin secreting cells or by administering to the subject a transplant composition comprising insulin secreting cells (e.g., β cells) genetically modified to over express GFR-α1 and c-Ret.
A · US 2008/0187522 A1 · ¶ 45
Also disclosed herein is the use of the AIPCs for implantation into a mammal for in vivo therapy, specifically for pancreatic disorders, including diabetes type I.
B · US 2021/0205371 A1 · abstract
An empty cell means only that no passage was reproduced there.
Statements in these documents
The islets are often severely injured from storage conditions or transport time causing apoptosis of the insulin secreting β-cells.
A · US 2008/0187522 A1 · ¶ 4
More specifically, the compositions and methods are related to activation of glial derived neurotrophic factor (GDNF) receptors or overexpression of the GFR-α1/c-Ret receptor complex in insulin secreting cells so as to promote cell survival and proliferation.
A · US 2008/0187522 A1 · ¶ 5
The study of diabetes and islet biology has been severely limited by the inability to culture and expand islet cells.
B · US 2021/0205371 A1 · ¶ 4
This inability to culture and propagate islet cells also limits the capability of islet cell replacement therapy which is a potential cure for diabetes.
B · US 2021/0205371 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355256 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355256/, SHA-256 ea69501e38de1c284f9194d296b5edd370055d97132964a1018afbd7498282a9